Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retrospective pharmacogenetic analysis of alisporivir-treated hepatitis C patients
2011-003559-21Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of alisporivir in hepatitis C virus infection (3 cohorts), sponsored by Novartis. Primary endpoint: Association of genetic variation with early viral response. Started Dec 2011; status: completed.
02
Drugs
alisporivir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2011-003559-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003559-21.